ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 59 filers reported holding ALPINE IMMUNE SCIENCES INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $243,885 | +32.4% | 21,300 | +18.9% | 0.00% | – |
| Q2 2023 | $184,165 | +1.5% | 17,915 | -23.8% | 0.00% | – |
| Q1 2023 | $181,420 | +4.3% | 23,500 | -0.7% | 0.00% | – |
| Q4 2022 | $173,946 | +270.1% | 23,666 | +259.1% | 0.00% | – |
| Q3 2022 | $47,000 | -44.7% | 6,591 | -33.3% | 0.00% | – |
| Q2 2022 | $85,000 | -38.4% | 9,875 | -36.1% | 0.00% | – |
| Q1 2022 | $138,000 | +100.0% | 15,442 | +212.3% | 0.00% | – |
| Q4 2021 | $69,000 | +91.7% | 4,944 | +46.7% | 0.00% | – |
| Q3 2021 | $36,000 | +80.0% | 3,371 | +51.4% | 0.00% | – |
| Q2 2021 | $20,000 | +66.7% | 2,226 | +89.0% | 0.00% | – |
| Q1 2021 | $12,000 | – | 1,178 | +3962.1% | 0.00% | – |
| Q2 2020 | $0 | -100.0% | 29 | -92.1% | 0.00% | – |
| Q3 2019 | $1,000 | – | 366 | +2514.3% | 0.00% | – |
| Q2 2019 | $0 | -100.0% | 14 | -98.7% | 0.00% | – |
| Q4 2018 | $4,000 | – | 1,105 | +55150.0% | 0.00% | – |
| Q2 2018 | $0 | -100.0% | 2 | -99.7% | 0.00% | – |
| Q1 2018 | $5,000 | – | 640 | +15900.0% | 0.00% | – |
| Q3 2017 | $0 | – | 4 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 2,571,450 | $23,143,000 | 2.13% |
| Omega Fund Management, LLC | 1,284,900 | $11,564,000 | 1.31% |
| Avidity Partners Management LP | 1,495,000 | $13,455,000 | 0.36% |
| Samsara BioCapital, LLC | 275,169 | $2,477,000 | 0.31% |
| Orbimed Advisors | 3,070,955 | $27,639,000 | 0.28% |
| Ikarian Capital, LLC | 300,454 | $2,704,000 | 0.22% |
| TIGER MANAGEMENT L.L.C. | 137,728 | $1,240,000 | 0.22% |
| DAFNA Capital Management LLC | 113,302 | $1,020,000 | 0.21% |
| EcoR1 Capital, LLC | 522,635 | $4,704,000 | 0.18% |
| Artal Group S.A. | 593,030 | $5,337,000 | 0.11% |